ARTICLE | Clinical News
Poteligeo mogamulizumab: Preliminary Phase II data
June 27, 2016 7:00 AM UTC
Preliminary data from an open-label, international Phase II trial in 71 patients with relapsed or refractory ATL showed that 1 mg/kg Poteligeo every week for 4 weeks followed by every other week led t...